Georgia's Online Cancer Information Center

Find A Clinical Trial

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Status
Active
Cancer Type
Solid Tumor
Unknown Primary
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT06586515
Protocol IDs
27189 (primary)
NCI-2024-08912
J5J-OX-JZZA
Study Sponsor
Eli Lilly and Company

Summary

The main purpose of this study is to assess safety & tolerability and antitumor activity
of LY3962673 as monotherapy and in combination with other chemotherapy agents in
participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to
last approximately 5 years.

Eligibility

  1. Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  2. Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA
  3. Have an ECOG performance status of = 1
  4. Must have received = 1 prior line of systemic chemotherapy for advanced or metastatic disease
  5. Participants with asymptomatic or treated CNS disease may be eligible.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.